PD-L1 抑制剂改善三阴性乳腺癌患者的生存。
PD-L1 Inhibitor Improves Survival in TNBC.
出版信息
Cancer Discov. 2019 Jan;9(1):OF5. doi: 10.1158/2159-8290.CD-NB2018-154. Epub 2018 Nov 21.
Abstract
Combining the PD-L1 inhibitor atezolizumab with standard chemotherapy improves overall survival among patients with metastatic triple-negative breast cancer relative to chemotherapy alone. These findings could lead to a new treatment option for patients with this disease.
摘要
PD-L1 抑制剂阿替利珠单抗联合标准化疗可改善转移性三阴性乳腺癌患者的总生存期，优于单独化疗。这些发现可能为该疾病患者提供一种新的治疗选择。
Zotero 插件